Click on image to view larger version.

Figure 5 Sensitivity analysis of fractional non-inferiority for Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation V trial. Non-inferiority, assessed at 0.5 fraction retention of the warfarin treatment, is supported if one-sided p 0.025 (represented by the lower dashed line). Superiority to placebo and warfarin is assessed at 0 and 1.0 fraction, respectively. The point estimate and the lower and upper limit of one-sided 97.5% confidence interval (CI) (equivalent to two-sided 95% CI) of the fraction of warfarin’s effect preserved by ximelagatran are shown as fractional values corresponding to the 50th (middle dashed line), 2.5th (lower dashed line), and 97.5th (upper dashed line) percentile of distribution, respectively.